FY2024 EPS Estimates for Glaukos Raised by Zacks Research

Glaukos Co. (NYSE:GKOS) – Equities researchers at Zacks Research boosted their FY2024 earnings per share estimates for Glaukos in a research note issued to investors on Monday, November 25th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of ($1.98) for the year, up from their previous estimate of ($2.32). The consensus estimate for Glaukos’ current full-year earnings is ($1.91) per share. Zacks Research also issued estimates for Glaukos’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.50) EPS.

Several other research firms also recently commented on GKOS. Truist Financial lifted their price objective on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Piper Sandler set a $140.00 price target on Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus raised their price objective on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. BTIG Research upped their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.45.

Glaukos Stock Performance

Shares of Glaukos stock opened at $143.81 on Thursday. The company has a 50 day moving average price of $133.81 and a 200 day moving average price of $124.52. The firm has a market capitalization of $7.93 billion, a P/E ratio of -47.62 and a beta of 1.02. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 52 week low of $59.58 and a 52 week high of $146.86.

Institutional Trading of Glaukos

A number of institutional investors and hedge funds have recently modified their holdings of the stock. O Shaughnessy Asset Management LLC purchased a new stake in Glaukos during the 1st quarter worth approximately $294,000. Cetera Advisors LLC acquired a new position in Glaukos in the 1st quarter valued at $213,000. Opaleye Management Inc. purchased a new position in Glaukos in the 1st quarter valued at $809,000. GAMMA Investing LLC lifted its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. Finally, LVW Advisors LLC acquired a new stake in Glaukos during the 2nd quarter worth $213,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.